World Alzheimer’s Day 2022

An estimated 50 million people around the world currently live with Alzheimer's disease or other dementias, dementia being a collective term for progressive syndromes that affect various expressions of cognitive function, such as memory and emotional expression. Alzheimer’s disease accounts for the majority of cases (50 to 70%, varying by country, based on Alzheimer’s Disease International and World Health Organization figures). For those directly affected and their loved ones, dementia can be a frightening experience, particularly as it is so poorly understood. However there remains little or no understanding of dementia in many, and the stigmatization and misinformation that surrounds dementia remains a global issue.

For 2022 World Alzheimer’s Day the theme Know Dementia, Know Alzheimer’s, organized annually by Alzheimer’s Disease International, focuses on diagnosis, the warning signs of dementia, with a special focus on post-diagnosis support. The aim of this international campaign is to highlight the importance of support for people living with dementia and families following a diagnosis.

Current Topics in Developmental Biology - Chapter 4: Improving mouse models for the study of Alzheimer's disease

The Neurobiology of Aging and Alzheimer Disease in Down Syndrome - Chapter 16: Clinical trials for Alzheimer’s disease in Down syndrome

The Neurobiology of Aging and Alzheimer Disease in Down Syndrome - Chapter 9: PET imaging in Down syndrome and Alzheimer’s disease

The Neurobiology of Aging and Alzheimer Disease in Down Syndrome - Chapter 10: Genetics of Alzheimer’s disease in adults with Down syndrome

Alzheimer's Disease - Chapter 8: Operational aspects of deep learning solutions for Alzheimer’s disease

Handbook of Decision Support Systems for Neurological Disorders - Chapter 5: Artificial intelligence for risk prediction of Alzheimer’s disease: a new promise for community health screening in the older aged

Alzheimer's Disease - Chapter 9: Treatment of depression in Alzheimer’s disease

Sex and Gender Differences in Alzheimer's Disease - Chapter 12: Gender and socioeconomic differences in modifiable risk factors for Alzheimer’s disease and other types of dementia throughout the life course

Alzheimer's Disease - Chapter 1: Measures of depression in Alzheimer’s disease

Autophagy in Health and Disease - Chapter 20: Autophagic processes in early- and late-onset Alzheimer’s disease

Assessments, Treatments and Modeling in Aging and Neurological Disease - Chapter 47: Nonhuman primates as models for aging and Alzheimer’s disease

International Review of Neurobiology - Chapter 4: Deep brain stimulation in Alzheimer's disease

Diagnosis and Management in Dementia - Chapter 19: The neuroscience of dementia: Diagnosis and management methods of amyloid positron emission tomography imaging and its application to the Alzheimer’s disease spectrum

Diagnosis and Management in Dementia - Chapter 9: Genetics of dementia: A focus on Alzheimer’s disease

Handbook of Mental Health and Aging - Chapter 14: Alzheimer’s disease and other neurocognitive disorders

Diagnosis and Management in Dementia - Chapter 40: Acetylcholinesterase inhibitory agents in plants and their application to dementia: Alzheimer’s disease

Neuroprotection in Alzheimer's Disease - Chapter 2: Neural Regeneration as a Disease-Modifying Therapeutic Strategy for Alzheimer's Disease

Handbook of Clinical Neurology, vol 179 - Chapter 19: Diurnal and seasonal molecular rhythms in the human brain and their relation to Alzheimer disease

Handbook of Clinical Neurology, vol 184 - Chapter 31: Alzheimer disease and neuroplasticity

Biomarkers in Alzheimer's Disease - Chapter 1: Introduction to Alzheimer’s Disease Biomarkers

Diagnosis and Treatment of Traumatic Brain Injury - Chapter 3: Thirty years post-injury: Impact of traumatic brain injury on later Alzheimer’s disease

Diseases of the Nervous System - Chapter 4: Aging, Dementia, and Alzheimer Disease

Exercise to Prevent and Manage Chronic Disease Across the Lifespan - Chapter 31: Exercise and Alzheimer’s disease

Genetics, Neurology, Behavior, and Diet in Dementia - Chapter 52: Alzheimer model 5xfad mice and applications to dementia: transgenic mouse models, a focus on neuroinflammation, microglia, and food-derived components

Human Caspases and Neuronal Apoptosis in Neurodegenerative Diseases - Chapter 2: Role of caspases, apoptosis and additional factors in pathology of Alzheimer's disease

Nanomedical Drug Delivery for Neurodegenerative Diseases - Chapter 14: Nanoparticle-mediated delivery of AChE inhibitors for the treatment of Alzheimer’s disease

Neurobiology of Brain Disorders - Chapter 19: Alzheimer diseases

Neurochemical Aspects of Alzheimer's Disease - Chapter 2: Risk Factors for Alzheimer’s Disease

Plant Extracts in Neurodegenerative Diseases - Chapter 1: Effect of plant extracts against Alzheimer’s disease

Economic costs of dementia in 11 countries in Europe: Estimates from nationally representative cohorts of a panel study

Alzheimer's disease amyloid-β pathology in the lens of the eye

Trans-urocanic acid facilitates spatial memory, implications for Alzheimer's disease

What kinds of social networks protect older adults’ health during a pandemic? The tradeoff between preventing infection and promoting mental health

Cardiometabolic multimorbidity, genetic risk, and dementia: a prospective cohort study

People living with dementia collaborating in a joint activity

Assisted eating in late-stage dementia: Intercorporeal interaction

Theranostic F-SLOH mitigates Alzheimer's disease pathology involving TFEB and ameliorates cognitive functions in Alzheimer's disease models

The Journeying through Dementia psychosocial intervention versus usual care study: a single-blind, parallel group, phase 3 trial

The multimodal action of genistein in Alzheimer's and other age-related diseases

Editor's Choice – Effect of Carotid Endarterectomy on 20 Year Incidence of Recorded Dementia: A Randomised Trial

Soluble TREM2 in CSF and its association with other biomarkers and cognition in autosomal-dominant Alzheimer's disease: a longitudinal observational study

Dementia risk in a diverse population: A single-region nested case-control study in the East End of London

Role of melatonin in Alzheimer's disease: From preclinical studies to novel melatonin-based therapies

Global and regional spending on dementia care from 2000–2019 and expected future health spending scenarios from 2020–2050: An economic modelling exercise

Outdoor air pollution exposure and cognitive performance: findings from the enrolment phase of the CONSTANCES cohort

Clinical effectiveness of music interventions for dementia and depression in elderly care (MIDDEL): Australian cohort of an international pragmatic cluster-randomised controlled trial

Identifying health conditions associated with Alzheimer's disease up to 15 years before diagnosis: an agnostic study of French and British health records

Dementia care-sharing and migration: An intersectional exploration of family carers' experiences

Trends in and complications associated with mental health condition diagnoses during delivery hospitalizations

Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019

Dietary Fiber Intake is Associated with Cognitive Function in Older Adults: Data from the National Health and Nutrition Examination Survey

Safety and efficacy of losartan for the reduction of brain atrophy in clinically diagnosed Alzheimer's disease (the RADAR trial): a double-blind, randomised, placebo-controlled, phase 2 trial

Hospital-treated infectious diseases and the risk of dementia: a large, multicohort, observational study with a replication cohort

Predicting Survival in Thai Patients After Low Impact Hip Fracture Using Flexible Parametric Modelling: A Retrospective Cohort Study

Reelin changes hippocampal learning in aging and Alzheimer's disease

Reversing pathology in a preclinical model of Alzheimer's disease by hacking cerebrovascular neoangiogenesis with advanced cancer therapeutics

The effect of COVID-19 isolation measures on the cognition and mental health of people living with dementia: A rapid systematic review of one year of quantitative evidence

Metallobiology and therapeutic chelation of biometals (copper, zinc and iron) in Alzheimer's disease: Limitations, and current and future perspectives

Mortality rates in Alzheimer's disease and non-Alzheimer's dementias: a systematic review and meta-analysis

Blood cholesterol and risk of dementia in more than 1·8 million people over two decades: a retrospective cohort study

The burden of neurological disorders across the states of India: the Global Burden of Disease Study 1990-2019

Comparison of the predictive accuracy of multiple definitions of cognitive impairment for incident dementia: a 20-year follow-up of the Whitehall II cohort study

Assessment of common infections and incident dementia using UK primary and secondary care data: a historical cohort study

Culturally tailored therapeutic interventions for people affected by dementia: a systematic review and new conceptual model

Transportation physical activity earlier in life and areas of the brain related to dementia later in life

Cognitive and social activities and long-term dementia risk: the prospective UK Million Women Study

Circadian disturbances in Alzheimer's disease progression: a prospective observational cohort study of community-based older adults

Prevalence, risk factors, and management of dementia and mild cognitive impairment in adults aged 60 years or older in China: a cross-sectional study

Associations between physical frailty and dementia incidence: a prospective study from UK Biobank

Dementia prevention, intervention, and care: 2020 report of the Lancet Commission

Advanced glycation end products and protein carbonyl levels in plasma reveal sex-specific differences in Parkinson's and Alzheimer's disease

Clinical and biomarker changes of Alzheimer's disease in adults with Down syndrome: a cross-sectional study

Prediction of dementia risk in low-income and middle-income countries (the 10/66 Study): an independent external validation of existing models

The Limits of Advance Directives in Maintaining Autonomy in Patients with Advanced Dementia

This is Me: Evaluation of a boardgame to promote social engagement, wellbeing and agency in people with dementia through mindful life-storytelling

Alzheimer's disease amyloid-β pathology in the lens of the eye

Cardiometabolic multimorbidity, genetic risk, and dementia: a prospective cohort study

Pharmacological intervention in a transgenic mouse model improves Alzheimer's-associated pathological phenotype: Involvement of proteasome activation

The war against Alzheimer, the mitochondrion strikes back!

Nitric oxide, aging and aerobic exercise: Sedentary individuals to Master's athletes

AlphaScreen Identifies MSUT2 Inhibitors for Tauopathy-Targeting Therapeutic Discovery

Diagnostic biomarkers of Alzheimer's disease: A state-of-the-art review

Diagnostic biomarkers in Alzheimer's disease

Change point analyses in prodromal Alzheimer's disease

Current Topics in Developmental Biology - Chapter 4: Improving mouse models for the study of Alzheimer's disease

Elsevier, Current Topics in Developmental Biology, Volume 148, January 2022

This book chapter advances SDG 3 and 10 by presenting that (1) some of these depression scales do not correlate, suggesting that they assess different aspects of depression; (2) reports of depression in dementia vary based on depression in dementia scale used; and (3) severe memory impairment may impact the ability to assess depression in the patients using self-reports.

SDG:

Goal 3: Good health and well-being; Goal 10: Reduced inequalities

Tags:

Health and wellbeing; Health and population, Africa, Antarctica, Asia, Europe, Global, Middle East, North America, Oceania, Pacific, South America

The Neurobiology of Aging and Alzheimer Disease in Down Syndrome - Chapter 16: Clinical trials for Alzheimer’s disease in Down syndrome

Elsevier, The Neurobiology of Aging and Alzheimer Disease in Down Syndrome, Volume , 1 January 2021

This book chapter advances SDG #3 and #10 by providing therapeutic strategies that can be employed in clinical trials for AD in DS will be discussed as well as their underlying scientific rationale.

SDG:

Goal 3: Good health and well-being; Goal 10: Reduced inequalities

Tags:

Health and population; Health and wellbeing, Africa, Antarctica, Asia, Europe, Global, Middle East, North America, Oceania, Pacific, South America

The Neurobiology of Aging and Alzheimer Disease in Down Syndrome - Chapter 9: PET imaging in Down syndrome and Alzheimer’s disease

Elsevier, The Neurobiology of Aging and Alzheimer Disease in Down Syndrome, Volume , 1 January 2021

This book chapter advances SDG #3 and #10 by providing a brief history of PET imaging and the radiotracers that have had a significant impact for measuring the three signature AD-related neuropathologies related to AD and provides an overview of the research utilizing PET imaging in the DS population

SDG:

Goal 3: Good health and well-being; Goal 10: Reduced inequalities

Tags:

Health and population; Health and wellbeing, Africa, Antarctica, Asia, Europe, Global, Middle East, North America, Oceania, Pacific, South America

The Neurobiology of Aging and Alzheimer Disease in Down Syndrome - Chapter 10: Genetics of Alzheimer’s disease in adults with Down syndrome

Elsevier, The Neurobiology of Aging and Alzheimer Disease in Down Syndrome, Volume , 1 January 2021

This book chapter advances SDG #3 and #10 by discussing the advantages of performing genetic studies in people with DS, and then discussing the role of reported genes that are known to be associated with AD risk in adults with DS or in the general population. It also discusses how future longitudinal multiomic and imaging study can enhance our understanding of the biology of AD.

SDG:

Goal 3: Good health and well-being; Goal 10: Reduced inequalities

Tags:

Health and population; Health and wellbeing, Africa, Antarctica, Asia, Europe, Global, Middle East, North America, Oceania, Pacific, South America

Alzheimer's Disease - Chapter 8: Operational aspects of deep learning solutions for Alzheimer’s disease

Elsevier, Alzheimer’s Disease: Understanding Biomarkers, Big Data, and Therapy, Volume , 1 January 2021

This book chapter advances SDG #3 and #10 by discussing the operational aspects of deep learning solutions for Alzheimer’s disease, including the review of the advantages and limitations of using deep learning, and future directions on the applications of deep learning to Alzheimer’s disease.

SDG:

Goal 3: Good health and well-being; Goal 10: Reduced inequalities

Tags:

Health and population; Health and wellbeing, Africa, Antarctica, Asia, Europe, Global, Middle East, North America, Oceania, Pacific, South America

Handbook of Decision Support Systems for Neurological Disorders - Chapter 5: Artificial intelligence for risk prediction of Alzheimer’s disease: a new promise for community health screening in the older aged

Elsevier, Handbook of Decision Support Systems for Neurological Disorders, Volume , 1 January 2021

This book chapter advances SDG #3 and #10 by systematically appraises the concepts and promising benefits of AI technology within healthcare for AD risk prediction across communities, and its possible concerns to be tackled prior to large-scale implementation.

SDG:

Goal 3: Good health and well-being; Goal 10: Reduced inequalities

Tags:

Health and population; Health and wellbeing, Africa, Antarctica, Asia, Europe, Global, Middle East, North America, Oceania, Pacific, South America

Alzheimer's Disease - Chapter 9: Treatment of depression in Alzheimer’s disease

Elsevier, Alzheimer’s Disease: Understanding Biomarkers, Big Data, and Therapy, Volume , 1 January 2021

This book chapter advances SDG #3 and #10 by providing evidence that behavioral treatments are more effective than most pharmacological therapies at managing depression in Alzheimer’s disease.

SDG:

Goal 3: Good health and well-being; Goal 10: Reduced inequalities

Tags:

Health and population; Health and wellbeing, Africa, Antarctica, Asia, Europe, Global, Middle East, North America, Oceania, Pacific, South America

Sex and Gender Differences in Alzheimer's Disease - Chapter 12: Gender and socioeconomic differences in modifiable risk factors for Alzheimer’s disease and other types of dementia throughout the life course

Elsevier, Sex and Gender Differences in Alzheimer’s Disease, Volume , 1 January 2021

This book chapter advances SDG #3 and #10 by stressing that a population health approach and a focus on promoting equity in health and access to care are critical to reducing the risk of AD and other dementias.

SDG:

Goal 3: Good health and well-being; Goal 10: Reduced inequalities; Goal 5: Gender equality

Tags:

Health and population; Health and wellbeing, Africa, Antarctica, Asia, Europe, Global, Middle East, North America, Oceania, Pacific, South America

Alzheimer's Disease - Chapter 1: Measures of depression in Alzheimer’s disease

Elsevier, Alzheimer’s Disease: Understanding Biomarkers, Big Data, and Therapy, Volume , 1 January 2021

This book chapter advances SDG #3 and #10 by presenting that (1) some of these depression scales do not correlate, suggesting that they assess different aspects of depression; (2) reports of depression in dementia vary based on depression in dementia scale used; and (3) severe memory impairment may impact the ability to assess depression in the patients using self-reports.

SDG:

Goal 3: Good health and well-being; Goal 10: Reduced inequalities

Tags:

Health and population; Health and wellbeing, Africa, Antarctica, Asia, Europe, Global, Middle East, North America, Oceania, Pacific, South America

Autophagy in Health and Disease - Chapter 20: Autophagic processes in early- and late-onset Alzheimer’s disease

Elsevier, Autophagy in Health and Disease, Volume , 1 January 2021

This book chapter advances SDG #3 and #10 by reviewing the extant literature on autophagy in AD and covers recent progress on the molecular mechanisms of NAD+-dependent mitophagy/autophagy regulation and mechanisms underlying the anti-AD potential of NAD+. Further studies to define the NAD+-mitophagy/autophagy axis may shed light on novel therapeutics to treat AD and potentially provide insights into other neurodegenerative diseases.

SDG:

Goal 3: Good health and well-being; Goal 10: Reduced inequalities

Tags:

Health and population; Health and wellbeing, Africa, Antarctica, Asia, Europe, Global, Middle East, North America, Oceania, Pacific, South America

Assessments, Treatments and Modeling in Aging and Neurological Disease - Chapter 47: Nonhuman primates as models for aging and Alzheimer’s disease

Elsevier, Assessments, Treatments and Modeling in Aging and Neurological Disease: The Neuroscience of Aging, Volume , 1 January 2021

This book chapter advances SDG #3 and #10 by reviewing the use of nonhuman primates as a viable model of aging and neurodegeneration research.

SDG:

Goal 3: Good health and well-being; Goal 10: Reduced inequalities

Tags:

Health and population; Health and wellbeing, Africa, Antarctica, Asia, Europe, Global, Middle East, North America, Oceania, Pacific, South America

International Review of Neurobiology - Chapter 4: Deep brain stimulation in Alzheimer's disease

Elsevier, International Review of Neurobiology, Volume 159, January 2021

This book chapter advances SDG #3 and #10 by reviewing deep brain stimulation as a treatment for AD patients, reviewing the recent studies and issues associated with the treatment.

SDG:

Goal 3: Good health and well-being; Goal 10: Reduced inequalities

Tags:

Health and population; Health and wellbeing, Africa, Antarctica, Asia, Europe, Global, Middle East, North America, Oceania, Pacific, South America

Diagnosis and Management in Dementia - Chapter 19: The neuroscience of dementia: Diagnosis and management methods of amyloid positron emission tomography imaging and its application to the Alzheimer’s disease spectrum

Elsevier, Diagnosis and Management in Dementia: The Neuroscience of Dementia, Volume 1, Volume , 1 January 2020

This book chapter advances SDG #3 and #10 by outlining how both the asymptomatic and symptomatic predementia phases of AD, amyloid positivity using amyloid PET imaging could predict progression to AD dementia. Amyloid PET imaging can identify the status of Aβ deposition in the underlying AD pathophysiology, increase diagnostic certainty, and alter management. This approach could improve the diagnose and management for patients with memory loss or cognitive dysfunction.

SDG:

Goal 3: Good health and well-being; Goal 10: Reduced inequalities

Tags:

Health and population; Health and wellbeing, Africa, Antarctica, Asia, Europe, Global, Middle East, North America, Oceania, Pacific, South America

Diagnosis and Management in Dementia - Chapter 9: Genetics of dementia: A focus on Alzheimer’s disease

Elsevier, Diagnosis and Management in Dementia: The Neuroscience of Dementia, Volume 1, Volume , 1 January 2020

This book chapter advances SDG #3 and #10 by focusing on providing a brief overview of genes associated with sporadic (late-onset) Alzheimer's disease (AD).

SDG:

Goal 3: Good health and well-being; Goal 10: Reduced inequalities

Tags:

Health and population; Health and wellbeing, Africa, Antarctica, Asia, Europe, Global, Middle East, North America, Oceania, Pacific, South America

Handbook of Mental Health and Aging - Chapter 14: Alzheimer’s disease and other neurocognitive disorders

Elsevier, Handbook of Mental Health and Aging, Volume , 1 January 2020

This book chapter advances SDG #3 and #10 by reviewing background on neurocognitive disorders, approaches to diagnosis, and management of several of the more problematic psychiatric complications of dementia. Disorders reviewed include AD, vascular dementia, Lewy body disease, and frontotemporal dementia. Psychiatric symptoms reviewed include apathy, agitation, psychosis, depression, and anxiety.

SDG:

Goal 3: Good health and well-being; Goal 10: Reduced inequalities

Tags:

Health and population; Health and wellbeing, Africa, Antarctica, Asia, Europe, Global, Middle East, North America, Oceania, Pacific, South America

Diagnosis and Management in Dementia - Chapter 40: Acetylcholinesterase inhibitory agents in plants and their application to dementia: Alzheimer’s disease

Elsevier, Diagnosis and Management in Dementia: The Neuroscience of Dementia, Volume 1, Volume , 1 January 2020

This book chapter advances SDG #3 and #10 by providing an overview of natural AChE inhibitors extracted from plants and their therapeutic potential to treat AD.

SDG:

Goal 3: Good health and well-being; Goal 10: Reduced inequalities

Tags:

Health and population; Health and wellbeing, Africa, Antarctica, Asia, Europe, Global, Middle East, North America, Oceania, Pacific, South America

Neuroprotection in Alzheimer's Disease - Chapter 2: Neural Regeneration as a Disease-Modifying Therapeutic Strategy for Alzheimer's Disease

Elsevier, Neuroprotection in Alzheimer's Disease, Volume , 20 January 2017

This book chapter advances SDG #3 and #10 by reviewing neural regeneration–based therapeutic approaches as it represents a highly promising therapeutic strategy for AD, including research that CNTF small-molecule peptide mimetic has demonstrated that neural regeneration–based strategy can also be disease modifying for AD.

SDG:

Goal 3: Good health and well-being; Goal 10: Reduced inequalities

Tags:

Health and population; Health and wellbeing, Africa, Antarctica, Asia, Europe, Global, Middle East, North America, Oceania, Pacific, South America

Handbook of Clinical Neurology, vol 179 - Chapter 19: Diurnal and seasonal molecular rhythms in the human brain and their relation to Alzheimer disease

Elsevier, Handbook of Clinical Neurology, Volume 179, January 2021

This book chapter advances SDG #3 and #10 by reviewing the observed epidemiological links between normal and abnormal diurnal and seasonal rhythmicity, cognitive impairment, and ADRD. Then reviewing normal diurnal and seasonal rhythms of brain epigenetic modification and gene expression in model organisms. Finally, reviewing evidence for diurnal and seasonal rhythms of epigenetic modification and gene expression the human brain in aging, Alzheimer's disease, and other brain disorders.

SDG:

Goal 3: Good health and well-being; Goal 10: Reduced inequalities

Tags:

Health and population; Health and wellbeing, Africa, Antarctica, Asia, Europe, Global, Middle East, North America, Oceania, Pacific, South America

Handbook of Clinical Neurology, vol 184 - Chapter 31: Alzheimer disease and neuroplasticity

Elsevier, Handbook of Clinical Neurology, Volume 184, January 2022

This book chapter advances SDG #3 and #10 by reviewing studies that showed treatments with multiple sessions of rTMS can influence cognition in people with neurodegenerative diseases. The chapter also considers novel therapeutic approaches based on the clinical use of rTMS.

SDG:

Goal 3: Good health and well-being; Goal 10: Reduced inequalities

Tags:

Health and population; Health and wellbeing, Africa, Antarctica, Asia, Europe, Global, Middle East, North America, Oceania, Pacific, South America

Biomarkers in Alzheimer's Disease - Chapter 1: Introduction to Alzheimer’s Disease Biomarkers

Biomarkers in Alzheimer's Disease, 2016, Pages 3-23

This book chapter advances SDG #3 and #10 by providing a brief outline of AD epidemiology, the definition of an AD biomarker, the classification and features of AD, and AD risk factors, followed by a description of the structure and content of each of the following chapters and their focus on specific types of AD biomarkers.

SDG:

Goal 3: Good health and well-being; Goal 10: Reduced inequalities

Tags:

Health and population; Health and wellbeing, Africa, Antarctica, Asia, Europe, Global, Middle East, North America, Oceania, Pacific, South America

Diagnosis and Treatment of Traumatic Brain Injury - Chapter 3: Thirty years post-injury: Impact of traumatic brain injury on later Alzheimer’s disease

Diagnosis and Treatment of Traumatic Brain Injury, 2022, Pages 27-38

This book chapter advances SDG #3 and #10 by focusing on an emblematic delayed-onset pathology often seen after traumatic brain injury—Alzheimer’s disease—and explain its relationship with chronic traumatic encephalopathy.

SDG:

Goal 3: Good health and well-being; Goal 10: Reduced inequalities

Tags:

Health and population; Health and wellbeing, Africa, Antarctica, Asia, Europe, Global, Middle East, North America, Oceania, Pacific, South America

Diseases of the Nervous System - Chapter 4: Aging, Dementia, and Alzheimer Disease

Diseases of the Nervous System (Second Edition), 2021, Pages 81-107

This book chapter advances SDG #3 and #10 by introducing the basic foundation of aging, dementia and Alzheimer Disease, including clinical presentation, diagnosis and epidemiology.

SDG:

Goal 3: Good health and well-being; Goal 10: Reduced inequalities

Tags:

Health and population; Health and wellbeing, Africa, Antarctica, Asia, Europe, Global, Middle East, North America, Oceania, Pacific, South America

Exercise to Prevent and Manage Chronic Disease Across the Lifespan - Chapter 31: Exercise and Alzheimer’s disease

Exercise to Prevent and Manage Chronic Disease Across the Lifespan, 2022, Pages 413-421

This book chapter advances SDG #3 and #10 by outlining the pathophysiology associated with Alzheimer’s disease and provide an overview of the impact of exercise programs on cognition, physical functional abilities, behavioral, and psychological symptoms and quality of life.

SDG:

Goal 3: Good health and well-being; Goal 10: Reduced inequalities

Tags:

Health and population; Health and wellbeing, Africa, Antarctica, Asia, Europe, Global, Middle East, North America, Oceania, Pacific, South America

Genetics, Neurology, Behavior, and Diet in Dementia - Chapter 52: Alzheimer model 5xfad mice and applications to dementia: transgenic mouse models, a focus on neuroinflammation, microglia, and food-derived components

Genetics, Neurology, Behavior, and Diet in Dementia, The Neuroscience of Dementia, Volume 2, 2020, Pages 833-847

This book chapter advances SDG #3 and #10 by focusing on mouse models of Alzheimer’s disease (AD), especially the 5xFAD line.

SDG:

Goal 3: Good health and well-being; Goal 10: Reduced inequalities

Tags:

Health and population; Health and wellbeing, Africa, Antarctica, Asia, Europe, Global, Middle East, North America, Oceania, Pacific, South America

Human Caspases and Neuronal Apoptosis in Neurodegenerative Diseases - Chapter 2: Role of caspases, apoptosis and additional factors in pathology of Alzheimer's disease

Human Caspases and Neuronal Apoptosis in Neurodegenerative Diseases, 2022, Pages 69-151

This book chapter advances SDG #3 and #10 by reviewing the latest developments in the field of clinical diagnosis and pharmacotherapeutics have provided hope to ameliorate the behavioral changes and cognitive disturbances associated with the disease.

SDG:

Goal 3: Good health and well-being; Goal 10: Reduced inequalities

Tags:

Health and population; Health and wellbeing, Africa, Antarctica, Asia, Europe, Global, Middle East, North America, Oceania, Pacific, South America

Nanomedical Drug Delivery for Neurodegenerative Diseases - Chapter 14: Nanoparticle-mediated delivery of AChE inhibitors for the treatment of Alzheimer’s disease

Nanomedical Drug Delivery for Neurodegenerative Diseases, 2022, Pages 223-242

This book chapter advances SDG #3 and #10 by highlighting a few newly updated nano drug delivery technologies implemented in Alzheimer’s disease therapies and prospects for the future regarding potential molecular mechanisms of nano drug delivery methods

SDG:

Goal 3: Good health and well-being; Goal 10: Reduced inequalities

Tags:

Health and population; Health and wellbeing, Africa, Antarctica, Asia, Europe, Global, Middle East, North America, Oceania, Pacific, South America

Neurobiology of Brain Disorders - Chapter 19: Alzheimer diseases

Neurobiology of Brain Disorders (Second Edition), Biological Basis of Neurological and Psychiatric Disorders, 2022, Pages 313-336

This book chapter advances SDG #3 and #10 by reviewing several key topics that influence our understanding of pathogenic mechanisms and lead to the identification of novel therapeutic strategies. These include the diagnostic spectrum of MCI and AD, genetic risk alleles associated with late-onset AD, structures of gamma-secretase and tau, imaging and fluid biomarkers, the role of microglia and neuroinflammation, and novel animal models of AD.

SDG:

Goal 3: Good health and well-being; Goal 10: Reduced inequalities

Tags:

Health and population; Health and wellbeing, Africa, Antarctica, Asia, Europe, Global, Middle East, North America, Oceania, Pacific, South America

Neurochemical Aspects of Alzheimer's Disease - Chapter 2: Risk Factors for Alzheimer’s Disease

Neurochemical Aspects of Alzheimer's Disease Risk Factors, Pathogenesis, Biomarkers, and Potential Treatment Strategies, 2017, Pages 47-91

This book chapter advances SDG #3 and #10 by reviewing the risk factors for Alzheimer’s Disease, including normal aging, diet, sedentary lifestyle, sleep disturbances, genes [amyloid precursor protein (APP), presenilin 1 (PSEN1), PSEN2, and APOE], environmental factors, and epigenetic factors.

SDG:

Goal 3: Good health and well-being; Goal 10: Reduced inequalities

Tags:

Health and population; Health and wellbeing, Africa, Antarctica, Asia, Europe, Global, Middle East, North America, Oceania, Pacific, South America

Plant Extracts in Neurodegenerative Diseases - Chapter 1: Effect of plant extracts against Alzheimer’s disease

Plant Extracts in Neurodegenerative Diseases, 2022, Pages 1-15

This book chapter advances SDG #3 and #10 by focusing on polyphenols and flavonoids and their crucial role in decreasing AD symptoms. In addition, it highlights the neuroprotective role of various essential ingredients of plant extracts such as Icariside, Onjisaponin B, Asarones, Liquiritin, Tanshinone IIA (TIIA) and cryptotanshinone (CT), Ginsenoside Rg1, and n-Butylidenephthalide. The efficacy of green nanotechnology are also discussed.

SDG:

Goal 3: Good health and well-being; Goal 10: Reduced inequalities

Tags:

Health and population; Health and wellbeing, Africa, Antarctica, Asia, Europe, Global, Middle East, North America, Oceania, Pacific, South America

Economic costs of dementia in 11 countries in Europe: Estimates from nationally representative cohorts of a panel study

Share of direct out-of-pocket, informal care, and direct public and private health and LTC insurance costs of dementia in 2018.

Elsevier, The Lancet Regional Health - Europe, Volume 20, September 2022

An article on dementia and Alzheimer's disease costs, in the context of SDG 3, focusing specifically on the economic costs of care in Europe.

World Alzheimer’s Day 2022

Table of contents

SDG:

Tags:

SDG:

Tags:

SDG:

Tags:

SDG:

Tags:

SDG:

Tags:

SDG:

Tags:

SDG:

Tags:

SDG:

Tags:

SDG:

Tags:

SDG:

Tags:

SDG:

Tags:

SDG:

Tags:

SDG:

Tags:

SDG:

Tags:

SDG:

Tags:

SDG:

Tags:

SDG:

Tags:

SDG:

Tags:

SDG:

Tags:

SDG:

Tags:

SDG:

Tags:

SDG:

Tags:

SDG:

Tags:

SDG:

Tags:

SDG:

Tags:

SDG:

Tags:

SDG:

Tags:

SDG:

Tags:

SDG:

Tags:

SDG:

Tags:

SDG:

Tags:

SDG:

Tags:

SDG:

Tags:

SDG:

Tags:

SDG:

Tags:

SDG:

Tags:

SDG:

Tags:

SDG:

Tags:

SDG:

Tags: